European Polyolefins Outlook 2018

August 22, 2018

European polyethylene (PE) and polypropylene (PP) editor Linda Naylor looks at the potential impact of new North American capacities on the European polyethylene market and looks at the divergent path PE and PP markets will take in 2018. Download our exclusive outlook to examine the trends and key drivers for PP and PE markets, with an in-depth look at the challenges, threats, and opportunities that lie ahead.

Spotlight

Verastem

Verastem, Inc. is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent non-Hodgkin lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells.

OTHER WHITEPAPERS
news image

Preventing Corrosion Resulting from Renewables Conversion

whitePaper | September 6, 2022

Many oil and gas companies are repurposing refineries to produce renewable diesel, sustainable aviation fuel, and other renewable biofuels and products. Their process equipment will now be faced with new chemical compositions, pressures, and temperatures.

Read More
news image

2020 oil, gas, and chemical industry outlook

whitePaper | February 26, 2020

As we, once again, move from one year to the next, how do we assess the oil and gas and chemical sectors’ performance in 2019 and its prospects for 2020? As always, there are headwinds and tailwinds, risks and opportunities, uncertainties and foreseeable trends, but in this report we aim to take stock of the main factors to watch for in 2020 across the diverse oil, gas, and chemical industry.

Read More
news image

Chemical Recyclingin a Circular Economy for Plastics

whitePaper | April 11, 2022

Chemical recycling is the only way to recycle large volumes of flexible plastics packaging and other mixed polyethylene/polypropylene into food grade PE/PP recycled content. Once operating at industrial scale, chemical recycling has the potential to recycle post-consumer flexible plastics “in practice and at scale».

Read More
news image

CHEMICAL (RE)ACTION

whitePaper | January 15, 2022

While sustainability has long been on the chemical industry agenda, the value paradigm is shifting fast.

Read More
news image

Tech Trends 2022

whitePaper | December 21, 2022

Over the past two years, the world has been reeling from the shock of the pandemic, and we are now collectively trying to navigate to our “next normal.” Those of us on the Tech Trends team believe that this represents the opportunity to engineer a better future—not to just.

Read More
news image

Chemicals supply chain: how to catch up the race!

whitePaper | December 13, 2019

The chemical industry has enjoyed strong and consistent performance over the last decade. The market is now being affected by new challenges, from increased global competition and changing customer requirements to disruptive new technologies while increased demand for sustainability, safety, and efficiency is changing not only the way companies work, but the products they produce.

Read More

Spotlight

Verastem

Verastem, Inc. is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent non-Hodgkin lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells.

Events